Plasma Glucagon-like Peptide-1 Levels and In-hospital Complications in ST-segment Elevation Myocardial Infarction

Bleeding Clinical Trial

Official title:

Plasma Glucagon-like Peptide-1 Levels Predict In-hospital Complications in ST-segment Elevation Myocardial Infarction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03314844
• Other study ID #: GLP1-IHC
• Status: Completed
• Phase: N/A
• First received: October 16, 2017
• Last updated: October 19, 2017
• Start date: February 1, 2013
• Est. completion date: February 1, 2015

Study information

• Verified date: October 2017
• Source: Chinese PLA General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Glucagon-like peptide-1 (GLP-1), produced mainly in enteroendocrine cells, participates in energy homeostasis and glucose metabolism by regulating islet hormone secretion, gastrointestinal motility, and food intake, making GLP-1 agonist a treatment for diabetes and obesity. Pre-clinical and clinical studies have demonstrated that GLP-1 also has cardio-protection effects. GLP-1 agonists is able to improve markers of cardiac function, reduce myocardial infarct size and post-myocardial infarction remodeling in experimental myocardial infarction. And GLP-1 infusion improved left ventricular function and increases myocardial salvage in patients with acute myocardial infarction (AMI). The investigators' previous study found that GLP-1 analogues attenuated ischemia-reperfusion induced apoptosis of stem- and myocardial microvascular endothelial cells, and liraglutide (a GLP-1 analog) usage during hospital stay can prevent no-reflow and improve heart function in AMI. Therefore, the investigators carried out a cohort study to evaluate the association between plasma GLP-1 and in-hospital complications in patients with ST-segment elevation myocardial infarction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 564
• Est. completion date: February 1, 2015
• Est. primary completion date: February 1, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• a diagnosis of STEMI and needed PCI

Exclusion Criteria:

• patients with cancer patients who used DPP4 inhibitor patients who used GLP1 analogue

Related Conditions & MeSH terms

• Bleeding
• Complications
• Glucagon-like Peptide-1
• Infarction
• Myocardial Infarction
• ST Elevation Myocardial Infarction
• STEMI - ST Elevation Myocardial Infarction

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Chinese PLA General Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	in-hospital complications	defined as acute heart failure, atrial fibrillation, chest pain or re-acute myocardial infarction, complete atrioventricular block, cerebrovascular disease, ventricular fibrillation or ventricular tachycardia	Time Frame: up to 2 week after PCI (until discharge)
Secondary	in-hospital major adverse cardiac or cerebrovascular events	the composite of death, nonfatal MI, or stroke	Time Frame: up to 2 week after PCI (until discharge)]
Secondary	in-hospital major bleeding	defined as absolute hemoglobin drop (baseline to nadir)=4g/dl, intracranial hemorrhage, retroperitoneal hemorrhage, use of red blood cell transfusion in patients with a baseline hemoglobin =9.0 g/dl, and use of red blood cell transfusion among patients with a baseline hemoglobin <9.0 g/dl and a witnessed bleeding event	Time Frame: up to 2 week after PCI (until discharge)